WA
BMRN icon

WPG Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History

WPG Advisers’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.73K Buy
170
+1
+0.6% +$55 0.01% 773
2026
Q1 		$9.55K Buy
169
+17
+11% +$991 0.01% 690
2025
Q4 		$9.03K Sell
152
-65
-30% -$3.54K 0.01% 734
2025
Q3 		$11.8K Buy
217
+133
+158% +$7.61K 0.01% 652
2025
Q2 		$4.62K Buy
84
+8
+11% +$471 ﹤0.01% 907
2025
Q1 		$5.37K Buy
76
+69
+986% +$4.64K 0.01% 856
2024
Q4 		$460 Buy
+7
New +$469 ﹤0.01% 1352

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

WPG Advisers's BMRN Position: Q2 2026 in Review

WPG Advisers increased its BioMarin Pharmaceuticals (BMRN) stake by 0.59% in Q2 2026, buying an estimated $55 and bringing the position to 170 shares worth $9.73K. The position accounts for 0.01% of the portfolio, ranked #773.

WPG Advisers first reported a position in BMRN in Q4 2024 and has held it in 7 quarters since. The position peaked at $11.8K in Q3 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • WPG Advisers held 170 shares of BioMarin Pharmaceuticals worth $9.73K as of Q2 2026.
  • WPG Advisers bought 1 BioMarin Pharmaceuticals share in Q2 2026, an estimated $55.
  • BioMarin Pharmaceuticals made up 0.01% of WPG Advisers's portfolio in Q2 2026, its #773 holding.
  • WPG Advisers first reported a position in BioMarin Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • WPG Advisers's BioMarin Pharmaceuticals position peaked at $11.8K in Q3 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on WPG Advisers's 13F filing for Q2 2026, filed 6 Aug 2026.